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 ABSTRACT 
Purpose: Ventricular-arterial (V-A) decoupling decreases myocardial efficiency and is exacerbated 
by tachycardia that increases static arterial elastance (Ea). We thus investigated the effects of heart 
rate (HR) reduction on Ea in septic shock patients using the beta-blocker esmolol. We hypothesized 
that esmolol improves Ea by positively affecting the tone of arterial vessels and their responsiveness 
to HR-related changes in stroke volume (SV). 
Methods: After at least 24 hours of hemodynamic optimization, 45 septic shock patients, with a HR 
≥95 bpm and requiring norepinephrine to maintain mean arterial pressure (MAP) ≥65 mmHg, 
received a titrated esmolol infusion to maintain HR between 80-94 bpm. Ea was calculated as 
MAP/SV. All measurements, including data from right heart catheterization, echocardiography, 
arterial waveform analysis and norepinephrine requirements, were obtained at baseline and at 4 
hours after commencing esmolol.  
Results: The HR target was achieved in all patients and this was associated with a decrease in Ea 
(2.19 ± 0.77 vs. 1.72 ± 0.52 mmHg·l-1), arterial dP/dtmax (1.08 ± 0.32 vs. 0.89 ± 0.29 mmHg·ms-1) 
and a parallel increase in stroke volume (48 ± 14 vs. 59 ± 18 ml), all p<0.05. Cardiac output and 
ejection fraction remained unchanged whereas norepinephrine requirements were reduced (0.7 ± 0.7 
to 0.58 ± 0.5 µg·kg-1·min-1, p<0.05).  
Conclusions: HR reduction with esmolol effectively improved Ea while allowing adequate 
systemic perfusion in patients with severe septic shock who remained tachycardic despite standard 
volume resuscitation. As Ea is a major determinant of V-A coupling, its reduction may contribute to 
improving cardiovascular efficiency in septic shock. 
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INTRODUCTION 
 
Despite achieving recommended hemodynamic targets [1], ventricular-arterial (V-A) 
decoupling may persist in patients with septic shock [2,3]. This decoupling is further 
exacerbated both by an increase in afterload through administration of vasoconstrictor agents, 
[2-4] and by tachycardia [5,6]. Decoupling is associated with cardiovascular inefficiency and 
unfavorable myocardial energetics that can deteriorate progressively during the course of the 
disease [2-6]. Tachycardia also increases myocardial oxygen consumption and, by shortening 
diastolic relaxation time, may impair coronary perfusion; these effects may further contribute 
to myocardial dysfunction and a poor outcome [7-12].  
We recently reported the impact of the short-acting selective beta1-adrenergic blocker esmolol 
on hemodynamics in a cohort of critically ill, fluid-resuscitated, septic shock patients with 
persistent tachycardia and high catecholamine requirements [10]. The esmolol-induced 
decrease in heart rate (HR) was associated with improved hemodynamics and reductions in 
norepinephrine dosing and troponin levels. This improvement may be related, at least in part, 
to enhanced diastolic function and/or better V-A coupling [13,14]. 
As arterial tone is a major determinant of V-A coupling [2,3,13,14], HR reduction may 
improve V-A coupling by decreasing static arterial elastance (Ea) [13,14]. As Ea is linearly 
determined by stroke volume (SV), any improvement in diastolic time and filling can directly 
influence Ea. The purpose of the present prospective observational study was to investigate 
the effects of HR reduction on Ea in tachycardic septic shock patients. We hypothesized that 
esmolol improves Ea by positively affecting the tone of arterial vessels and their 
responsiveness to HR-related changes in stroke volume. 
 
 
METHODS 
Patients 
The study was undertaken in an 18-bed multidisciplinary intensive care unit (ICU) ("La 
Sapienza”, University of Rome, Policlinico Umberto I). An institutional review board 
provided ethical approval for the study (ClinicalTrials.gov NCT02188888). Enrolment 
occurred between December 2013 and June 2014. Consent was waived as patients at study 
entry were not able to provide informed consent. Permission to use collected data was 
obtained from the patient when mental competency was regained or, otherwise, their next-of-
kin.  
We enrolled septic shock patients who, despite adequate fluid resuscitation, were still 
requiring high-dose norepinephrine (NE) to maintain a mean arterial pressure (MAP) ≥65 
mmHg [1], and had a tachycardia >95 beats per minute (bpm) after 24 hours [10].   
Exclusion criteria were: age <18 years, cardiac dysrhythmias, need for an inotropic agent, 
significant valvular heart disease and pregnancy. All patients were sedated with remifentanil 
and propofol, and received volume-controlled mechanical ventilation. 
Hemodynamic measurements 
Systemic hemodynamic monitoring included pulmonary artery (7.5F, Edwards Lifesciences, 
Irvine, CA, USA) and radial artery catheterization. MAP, central venous pressure (CVP), 
mean pulmonary arterial pressure (MPAP), and pulmonary arterial occlusion pressure (PAOP) 
measured at end-expiration. HR was measured from continuous electrocardiographic 
recording. Cardiac output (COth) and stroke volume (SVth) was estimated by the continuous 
thermodilution technique (Vigilance II®, Edwards Lifesciences, Irvine, CA, USA).  
The radial artery catheter was connected to the MostCare® hemodynamic monitor (Vytech, 
Padua, Italy). This device utilizes the pressure recording analytic method (PRAM) to provide 
continuous beat-to-beat monitoring of stroke volume (SVp) with assessment of left ventricular 
function [15,16]. Measures obtained from analysis of the radial arterial pressure waveform 
contour were: systolic pressure (Psys), diastolic pressure (Pdia), dicrotic notch (Pdic) and MAP, 
peripheral artery dP/dtmax (art.dP/dtmax), cardiac cycle efficiency (CCE) [15,16]. After data 
acquisition, we calculated differences between MAP and Pdic (MAP - Pdic) [17,18] and cardiac 
power output (CPwO) [19].  
For calculation of Ea we applied the formula MAP/SV [2-6,20]. SV was calculated by using 
the thermodilution technique in which SVth = COth/HR. This was directly estimated from a 
single beat obtained by arterial waveform analysis (SVp) [15,16].  
Echocardiography 
Two-dimensional real-time echocardiographic studies were performed to assess left 
ventricular ejection fraction (LVEF), using a wide-angle phased-array digital sector scanner 
and a 5-MHz multiplane transesophageal probe (T6H, HD7 XE Philips, Eindhoven, The 
Netherlands). 
Study design 
After at least 24 hours of hemodynamic stabilization targeted at achieving values of PAOP 
≥12 mmHg, CVP ≥8 mmHg, and MAP ≥65 mmHg [1], those patients who remained with HR 
values ≥95 bpm were treated with a continuous esmolol infusion to maintain HR between 80-
94 bpm [10]. The protocol required a titrated esmolol infusion commenced at 25 mg•h-1, with 
an upper dose limit of 2000 mg•h-1, to maintain this predefined HR range [10]. During this 
intervention period, conventional treatment was continued as per usual practice. Fluid 
challenges were performed, and repeated as necessary, to maintain CVP ≥8 mmHg and PAOP 
≥12 mmHg [1]. Norepinephrine (NE) was titrated to maintain MAP ≥65 mmHg. None of the 
patients received inotropic support (levosimendan or dobutamine) during the intervention 
period. Hemodynamic and echocardiographic variables as well as NE requirements were 
determined at baseline and after four hours of esmolol infusion. Since our ICU guideline 
requires administration of esmolol to maintain the predefined HR threshold for the whole 
length of the patient’s stay in ICU, death from any cause was assessed at Day 28 after esmolol 
commencement. 
Statistical analysis  
All hemodynamic variables were evaluated before and after esmolol administration using 
Student’s t-test for paired data. Data were analyzed with IBM SPSS 20.0 statistical software 
(SPSS, Chicago, IL, USA). Values were reported as mean ± standard deviation (SD) or 
absolute values. Statistical significance was established at a two-tailed P level <0.05. 
Role of the funding source 
This study was funded by an independent research grant from the Department of 
Anesthesiology and Intensive Care of the University of Rome "La Sapienza”.  
 
 
RESULTS 
 
One hundred and sixteen septic shock patients were screened for enrollment and forty-five 
patients were included in the study (Fig 1). Their demographics and outcomes are 
summarized in Table 1. Twenty-two patients (49%) survived until Day 28. Of note, their 
norepinephrine requirements were high as in our previous study (10) and all patients received 
esmolol to maintain the predefined HR threshold for the whole length of the patient’s stay in 
ICU 
Hemodynamic and echocardiographic variables and norepinephrine requirements. 
The target range of 80-94 bpm was not achieved in all patients after 4 hours of esmolol 
infusion, as HR values were collected while performing transesophageal echocardiography 
and this procedure did, in some patients, induce brief HR fluctuations. In six patients HR 
transiently rose (to (101 ± 1.7 bpm), while in 5 patients HR transiently fell (to 70 ± 1.3bpm) 
(Figure 2). The protocol did not allow any modification in the level of sedation (thereby 
influencing afterload). Compared to baseline, there were significant decreases (all p <0.001) 
in Eath, Eap MAP, MPAP and norepinephrine requirements at the 4 hour timepoint, while SVp 
and SVth, CCE, and CPwO (all p<0.01). COp and COth and LVEF remained unchanged. 
(Table 2). No differences were found when comparing COp and COth as well as SVp and SVth 
at the study timepoints. 
Compared to baseline, while Pdic remained unchanged, Psys, Pdia, MAP - Pdic, and art.dP/dtmax 
significantly decreased after 4 hours’ esmolol infusion (all p<0.001) (Table 2). 
 
DISCUSSION 
We demonstrate that an esmolol infusion, given over 4 hours and titrated to reduce HR below 
95 bpm in a cohort of fluid-resuscitated septic shock patients, was associated with a decrease 
in Ea and a parallel increase in SV. CO and LVEF remained unchanged whereas 
norepinephrine requirements were reduced.  
The performance of the cardiovascular system depends on its ability to optimize coupling 
between the ventricle and arterial system [2,3,20]. In the presence of optimal V-A coupling, 
the cardiovascular system reaches its maximum efficiency; this implies that all the pulsating 
energy produced by the left ventricle is transmitted downstream to the peripheries with lower 
energy costs [2,3,20]. 
Sympathetic activation plays a pivotal role in matching the ventricle to the arterial system. 
The consequent rise in HR leads to an increase in myocardial contractility to match the 
concomitant increase in afterload due to the force–frequency response [2,3,20]. By contrast, 
in the septic heart, alterations in sarcoplasmic reticulum calcium handling and β-adrenergic 
receptor downregulation abolish the force–frequency effect on myocardial contractility [2,3,4, 
20,22]. Under such conditions tachycardia further decreases myocardial performance and thus 
worsens V-A coupling. Due to unfavorable cardiac energetics, such uncoupling will 
contribute to myocardial dysfunction [2-6]. 
An elevated HR is associated with an increased mortality risk in patients with septic shock [8-
12]. In agreement with other clinical and experimental studies [23,24], the reduction in HR 
with esmolol was accompanied by an increase in SV and did not cause significant 
cardiovascular derangement to any of our patients. For a similar preload, CO was not 
significantly reduced due to the concomitant increase in SV. Although MAP decreased, it 
remained within acceptable limits [1,25] while a reduction was achieved in norepinephrine 
requirements.  
The above findings confirm that, in the presence of an adequate preload, lowering HR allows 
better ventricular filling during diastole, hence increasing SV [7,23,24]. We hypothesized that 
beside the effects of HR reduction on diastolic function, the increase in SV was also the result 
of improved arterial loading as a consequence of a reduced Ea. In line with previous studies 
[13,14], we noticed a decrease in Ea after esmolol administration. This presents the result of 
the interplay between wall stiffness, compliance and outflow resistance, and thus expresses 
the true afterload imposed on the left ventricle [2-6,20]. Of note, changes in SV occurred 
while reducing NE requirements but without any change in LVEF. This indicates that the 
increase in SV was not the result of increased myocardial contractility but of better ventricular 
filling and reduced Ea. As LVEF may be largely affected by afterload in septic shock, a 
decrease in Ea also explains the finding of an unchanged LVEF after esmolol infusion [31]. 
Changes in Ea may be mediated by both enhanced endothelial function and modifications of 
the physical properties of the vasculature. Beta-blockers may improve endothelium-dependent 
relaxation by exerting anti-inflammatory activity, reducing vascular oxidative stress and 
modulating nitric oxide pathways [23,24,26-28]. On the other hand, by acting on the 
viscoelastic component of the vessel wall, HR per se may affect the tendency of the arterial 
vessels to distend in response to their intravascular pressure [29,30]. Since vessel 
distensibility is time-dependent, arterial vessels will have more a rigid structure if the time 
allowed for them to distend is reduced, as occurs during tachycardia [29,30]. HR reduction 
can therefore lead to arterial de-stiffening and increased compliance [13,14].   
Art.dP/dtmax decreased on reducing HR, while SV improved and NE requirements were 
reduced. These findings indicate that in addition to improved diastolic phase, reduced Ea 
allowed LV to generate a higher SV with less contractility and lower energetic cost (Fig 3). 
However, this decrease may be also caused by a direct effect of esmolol on myocardial 
contractility. To further elucidate the effects of HR reduction on cardiovascular performance 
we analyzed changes in MAP - Pdic. This is a true measure obtained from the pulse contour 
and accurately expresses the interaction between LV contractility and a given afterload 
[17,18]. This measure may indicate changes in contractility better than LVEF as the latter 
may be normal in septic shock despite a serious impairment of intrinsic LV contractility [31]. 
In healthy subjects the value of MAP - Pdic is very low as the level of MAP and Pdic are 
similar. By contrast, in septic shock the value of MAP - Pdic is high due to reduced arterial 
tone, reflecting an adaptive response to a decrease in SV. Indeed, a decrease in arteriolar 
resistance allows a higher SV at any given contractility and left ventricular filling. After HR 
reduction, we noticed a decrease in MAP - Pdic; this suggests that, in some patients, the 
afterload became potentially excessive for that level of contractility [4,17,18]. Nevertheless, 
even in this situation, HR reduction did not cause further cardiovascular derangement and the 
administration of esmolol was well tolerated. We hypothesized that an improved diastolic 
phase with better ventricular filling compensated for decreased contractility. It is therefore 
conceivable that, in some patients, improved diastolic function contributed more than the 
reduction in Ea towards increasing myocardial efficiency. Taken together, these results 
suggest that reducing HR in tachycardic septic shock patients with a beta-blocker will have 
variable effects, in particular on V-A coupling. This reinforces the need to individualize 
patient treatment according to both myocardial performance as well as their hemodynamic 
status. 
As previously discussed, the increase in SV after HR reduction contributed to the 
maintenance of cardiac output. This altered hemodynamic profile should be considered as an 
economization of myocardial workload and oxygen consumption, thereby lowering the risk of 
myocardial ischemia. Accordingly, both CCE, a surrogate of cardiac function and cardiac 
power output (the strongest hemodynamic correlates of mortality in heart failure [19]), 
improved on reducing HR. An improvement in V-A coupling due to reduced Ea, together 
with an economization of myocardial workload and oxygen consumption may contribute to 
preserving myocardial efficiency, especially in established septic shock. Although this 
hemodynamic profile has been associated with improved outcomes (10), this hypothesis 
remains to be tested in larger trials. 
There are several limitations to this study, the most important being that it was not designed 
as a randomized controlled trial. Such a design would best discriminate the effects of esmolol.	
Nevertheless, arterial elastance and myocardial performance can differ significantly between 
septic shock patients according to their preload, myocardial contractility, arterial stiffness and 
vasopressor support. Such variables and their relationships may vary considerably over time 
depending on disease progression. We therefore utilized a short-period observational design 
in which the patient served as his/her own control, rather than a randomized controlled design. 
We thus lack a control group so we cannot be certain that our findings are the consequence of 
the esmolol-induced reduction of HR rather than an independent evolution of the patient’s 
condition. However, the brief observational period of 4 hours allowed us to limit this bias, and 
there was a marked consistency of response to esmolol. We did not investigate ventricular 
elastance, the other determinant of V-A coupling. An accurate measure of ventricular 
elastance is, however, extremely difficult to perform in severely compromised septic shock 
patients due to the invasiveness and the risks of the technique. For the same safety concern, 
we analyzed changes in art dP/dtMAX rather than LV dP/dtMAX as it can be easily obtained in 
the majority of septic shock patients from their arterial pressure waveform. However, art 
dP/dtMAX is a surrogate measure; in the presence of vasoplegia (as in septic shock) this may 
not accurately reflect LV dP/dtmax.  
Since we enrolled only patients in a hyperdynamic state and with preserved LVEF after at 
least 24 hours of hemodynamic optimization, we cannot extrapolate our results to earlier 
phases of septic shock or to patients with lower LVEF or CO, for whom further investigations 
are needed. We also did not measure longer term changes to assess the evolution in 
ventricular performance characteristics, although a potential bias due to other confounding 
influences will be greater.  
CONCLUSION 
Despite achieving recommended hemodynamic targets, V-A decoupling may persist in 
patients with septic shock and it can deteriorate progressively during the course of the disease 
[2-4]. Such patients may potentially benefit from therapies aimed at normalizing V-A 
coupling. Among them, HR reduction with esmolol could effectively improve Ea while 
allowing adequate systemic perfusion in septic shock patients remaining tachycardic despite 
standard resuscitation. As Ea is a major determinant of V-A coupling, its reduction may 
contribute to improving cardiovascular efficiency in septic shock.  
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Figures: 
Fig 1. Study flowchart. CVP, central venous pressure; HR, heart rate; MAP, mean arterial pressure; 
NE, norepinephrine; PAOP, pulmonary arterial occlusion pressure; SSC, Surviving Sepsis 
Campaign. 
 
 
 
  
Fig 2. Scatterplot of HR values while performing transesophageal echocardiography at the end of 
the observational period. 
 
 
 
  
Fig 3. Example of an arterial waveform before (A) and after (B) reducing heart rate. Note the 
biphasic nature of the flow pattern during tachycardia, and the more physiological waveform after 
reducing heart rate with esmolol. Changes were achieved through an increase in SV as well as the 
ability of the cardiovascular system to increase arterial tone in response to an augmented SV. 
	
	
	
	
	 	
Table	1.	Characteristics	of	the	study	patients	(n	=	45)		
	
Age,	yrs	 61	±	18	
Gender,	male	 73%	
SAPS	II	 54	±	7	
28	day	mortality	 51%	
ICU	length	of	stay,	days	 18	±	17	
	
Data	given	as	mean	and	standard	deviation.	SAPS	II,	simplified	acute	physiology	score	II;	ICU,	intensive	care	
unit.	
	 	
Table	2.	Hemodynamic,	echocardiographic	and	arterial	waveform	data		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Data	given	as	mean	and	standard	deviation.	COth,		cardiac	output	obtained	with	thermodilution;	SVth,	stroke	
volume	obtained	with	thermodilution;	COp	cardiac	output	obtained	with	the	pulse	contour	analysis;	SVp,	
stroke	volume	obtained	with	the	pulse	contour	analysis;	HR,	heart	rate;	MAP,	mean	arterial	pressure;	
MPAP,	mean	pulmonary	arterial	pressure;	PAOP,	pulmonary	arterial	occlusion	pressure;	CVP,	central	
venous	pressure;	Eap,	arterial	elastance	obtained	with	the	pulse	contour	analysis;	Eath,		arterial	elastance	
obtained	with	thermodilution;	LVEF,	left	ventricular	ejection	fraction;	CCE,	cardiac	cycle	efficiency;	CPwO,	
cardiac	power	output;	NE,	norepinephrine,	Psys,	systolic	pressure;	Pdia,	diastolic	pressure;	Pdic,	dicrotic	
pressure.	*	See	figure	2	
	
Variable	 Baseline	 4	hours	 p	value	
COth	[L·min-1]	 5.4	±1.3	 5.1	±	1.4	 0.11	
SVth	[mL]	 48	±	14	 59	±	18	 <0.001	
COp	[L·min-1]	 5.1	±1.3	 5.0	±	1.3	 0.77	
SVp	[mL]	 47	±	12	 59	±	16	 <0.001	
HR	[min-1]	 115	±	11	 88	±	9	*	 <0.001	
SVR	[Dyn	•	s/cm5]	 1234±293	 1102±260	 0.001	
MAP	[mmHg]	 80	±	12	 75	±	10	 0.005	
MPAP	[mmHg]	 30	±	7	 28	±	6	 0.001		
PAOP	[mmHg]	 16	±	3	 16	±	4	 0.74		
CVP	[mmHg]	 12	±	3	 12	±	3	 0.86	
Eap		[mmHg·l-1]	 2.2	±	0.7	 1.7	±	0.5	 <0.001	
Eath	[mmHg·l-1]	 2.0	±	0.6	 1.55	±	0.5	 <0.001	
LVEF	[%]	 52	±	11	 53	±	11	 0.17	
Art	dP/dtMAX	[mmHg·ms-1]	 1.08	±	0.32	 0.89	±	0.29	 0.0009	
CCE	[units]	 -0.15	±	0.5	 -0.01	±	0.4	 0.002	
CPwO	[W]	 0.53	±	0.14	 0.63	±	0.24	 0.007	
NE	dosage	[µg·kg-1·min-1]	 0.7	±	0.7	 0.58	±	0.55	 0.01	
Psys	[mmHg]	 119	±	18	 110	±	18	 0.0003	
Pdia	[mmHg]	 61	±	12	 57	±	9	 0.0004	
Pdic	[mmHg]	 72	±	15	 70	±	12	 0.45	
MAP	-	Pdic	[mmHg]	 9.4	±	9	 4.3	±	8	 <0.0001	
